ICAAC update on opportunistic infections.
D'Amico
R
R
St. Luke's Medical Center, Rush Home Care Network, Chicago, IL.
D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D000666:Amphotericin B / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000627:therapeutic use; D017963:Azithromycin / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count / Q000187:drug effects; D002180:Candidiasis, Oral / Q000150:complications / Q000188:drug therapy*; D017291:Clarithromycin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D002991:Clofazimine / Q000627:therapeutic use; D003022:Clotrimazole / Q000627:therapeutic use; D015331:Cohort Studies; D004347:Drug Interactions; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D015725:Fluconazole / Q000627:therapeutic use*; D005437:Flucytosine / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use; D007654:Ketoconazole / Q000627:therapeutic use; D007917:Leprostatic Agents / Q000627:therapeutic use; D015270:Mycobacterium avium-intracellulare Infection / Q000188:drug therapy / Q000517:prevention & control*; D009761:Nystatin / Q000627:therapeutic use; D017828:Rifabutin / Q000627:therapeutic use; D016019:Survival Analysis
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D000995:Antitubercular Agents; D017320:HIV Protease Inhibitors; D007917:Leprostatic Agents; D009761:Nystatin; D017828:Rifabutin; D017964:Itraconazole; D000666:Amphotericin B; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D017963:Azithromycin; D015725:Fluconazole; D005437:Flucytosine; D002991:Clofazimine; D003022:Clotrimazole; D017291:Clarithromycin; D007654:Ketoconazole